Harmony Biosciences Holdings (HRMY) Tax Provisions (2021 - 2026)

Harmony Biosciences Holdings (HRMY) has 6 years of Tax Provisions data on file, last reported at $7.2 million in Q1 2026.

• For the quarter ending Q1 2026, Tax Provisions fell 38.03% year-over-year to $7.2 million; the trailing twelve-month figure through Mar 2026 stood at $9.2 million (down 79.35% YoY), and the FY2025 full-year result was $13.6 million, down 70.63% from the prior year.
• Tax Provisions rose to $7.2 million in Q1 2026, from -$24.5 million in the prior quarter.
• In the past five years, Tax Provisions ranged from a high of $16.6 million in Q3 2025 to a low of -$80.0 million in Q3 2022.
• A 5-year average of $2.1 million and a median of $9.8 million in 2023 frame the typical range for Tax Provisions.
• Across the five-year window, Tax Provisions slumped 8766.52% in 2022 and jumped 396.91% in 2023, its largest moves.
• Tracing HRMY's Tax Provisions over 5 years: stood at -$4.4 million in 2022, then jumped by 396.91% to $13.1 million in 2023, then plunged by 48.94% to $6.7 million in 2024, then plunged by 466.8% to -$24.5 million in 2025, then jumped by 129.38% to $7.2 million in 2026.
• Business Quant data shows HRMY's Tax Provisions at $7.2 million in Q1 2026, -$24.5 million in Q4 2025, and $16.6 million in Q3 2025.